The US Food and Drug Administration (FDA) has approved the clinical use of Fms-like tyrosine kinase 3 (FLT3) inhibitors, B cell leukemia/lymphoma 2 (BCL-2) inhibitors, histone deacetylase (HDAC) inhibitors, hypomethylating agents, histone methyltransferase inhibitors, and proteasome inhibitors as targeted cancer therapeutics (65, 66). The gene discussed is FLT3; the disease is cancer.